Turner Syndrome
Conditions
Brief summary
Changes in body composition examined by total body dual-energy x-ray absorptiometry (DXA-scan) including bone mass, visceral and subcutaneous fat mass, and lean muscle mass, as well as measures of abdominal circumference and weight.
Detailed description
Changes in quality of life, Changes in inflammatory markers, Changes in sexual function, Changes in intramuscular sex hormone levels, Changes in blood volume and hemoglobin mass, Changes in coagulation parameters, Changes in metabolic parameters, Changes in neurocognitive function, Changes in hypothalamus structure, Changes in VO2-max, physical activity, muscle function and strength
Interventions
DRUGISOPROPYL MYRISTATE
DRUGANDROGEL 25 mg
DRUGCARBOMER 980
DRUGSODIUM HYDROXIDE
DRUGETHANOL (96 PER CENT)
Sponsors
Region Midtjylland
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in body composition examined by total body dual-energy x-ray absorptiometry (DXA-scan) including bone mass, visceral and subcutaneous fat mass, and lean muscle mass, as well as measures of abdominal circumference and weight. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in quality of life, Changes in inflammatory markers, Changes in sexual function, Changes in intramuscular sex hormone levels, Changes in blood volume and hemoglobin mass, Changes in coagulation parameters, Changes in metabolic parameters, Changes in neurocognitive function, Changes in hypothalamus structure, Changes in VO2-max, physical activity, muscle function and strength | — |
Countries
Denmark
Outcome results
None listed